LONG-TERM OUTCOMES OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV VIA A COST-EFFECTIVENESS MODEL

被引：0
|
作者：
Vardanega, V. [1 ]
Rawlinson, W. [1 ]
Francis-Graham, S. [1 ]
Mezzio, D. [2 ]
Eddowes, L. A. [3 ]
机构：
[1] Costello Med, London, Lon, England
[2] Gilead Sci, Foster City, CA USA
[3] Costello Med, Cambridge, Cam, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE233
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 39 条
  • [1] US COST-EFFECTIVENESS OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV
    Vardanega, V.
    New, E.
    Mezzio, D.
    Eddowes, L. A.
    VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
  • [2] Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus
    Chatzidaki, Iro
    Curteis, Tristan
    Luedke, Hannah
    Mezzio, Dylan J.
    Rhee, Martin S.
    McArthur, Eve
    Eddowes, Lucy A.
    VALUE IN HEALTH, 2023, 26 (06) : 810 - 822
  • [3] US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance
    Vardanega, Vittoria
    New, Emma
    Mezzio, Dylan
    Eddowes, Lucy A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (09): : 1001 - 1012
  • [4] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment
    Davoudi-Monfared, Effat
    Taghizadeh-Ghehi, Maryam
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (03) : 621 - 622
  • [5] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment
    Effat Davoudi-Monfared
    Maryam Taghizadeh-Ghehi
    International Journal of Clinical Pharmacy, 2019, 41 : 621 - 622
  • [6] Cost-effectiveness of multi-drug regimen of amlodipine plus atorvastatin based on the anglo-scandinavian cardiac outcomes trial (ASCOT):: An economic sub-analysis
    Koren, Michael
    Lindgren, Peter
    Buxton, Martin
    Kahan, Thomas
    Poulter, Neil
    Dahlof, Bjorn
    Sever, Peter
    Wedel, Hans
    Tang, Simon S.
    Jonsson, Bengt
    CIRCULATION, 2007, 115 (21) : E568 - E568
  • [7] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia
    Cara, Abdul Karim Suleman
    Zaidi, Syed Tabish Razi
    Suleman, Fatima
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (05) : 1051 - 1058
  • [8] Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia
    Abdul Karim Suleman Cara
    Syed Tabish Razi Zaidi
    Fatima Suleman
    International Journal of Clinical Pharmacy, 2018, 40 : 1051 - 1058
  • [9] A New Type 2 DiabetesMicrosimulation Model to Estimate Long-Term Health Outcomes, Costs, and Cost-Effectiveness
    Hoerger, Thomas J.
    Hilscher, Rainer
    Neuwahl, Simon
    Cheng, Yiling J.
    Benoit, Stephen R.
    Shao, Hui
    Laxy, Michael
    Yang, Wenya
    Cintina, Inna
    Kaufmann, Matthew
    Chen, Haiying
    Anderson, Andrea M.
    Staimez, Lisa R.
    Venkat Narayan, K. M.
    Zhang, Ping
    DIABETES, 2021, 70
  • [10] Long-Term Outcomes After Hospitalization Among Intensive Care Patients with Multi-Drug Resistant Bacterial Infection or Colonization
    Kadura, S.
    Farhat, M. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
1234